ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Heart disease"

  • Abstract Number: 1500 • ACR Convergence 2020

    Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation

    Deborah Friedman1, Mimi Kim2, Nathalie Costedoat-Chalumeau3, Robert Clancy4, Joshua Copel5, Colin Phoon6, Bettina Cuneo7, Rebecca Cohen6, Mala Masson6, Benjamin Wainwright6, Noel Zahr8, Amit Saxena4, Peter Izmirly9 and Jill Buyon10, 1New York Medical College, Valhalla, 2Albert Einstein College of Medicine, Bronx, 3APHP, Université de Paris, Paris, France, 4NYU School of Medicine, New York, 5Yale School of Medicine, New Haven, 6New York University School of Medicine, New York, 7University of Colorado School of Medicine, Aurora, 8Pitié-Salpêtrière University Hospital, Paris, France, 9Department of Medicine, New York University School of Medicine, New York, NY, 10Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Based on inhibition of viral replication and limited reports on clinical efficacy, hydroxychloroquine (HCQ) was initially considered as a prophylaxis and treatment of COVID-19. …
  • Abstract Number: 1667 • ACR Convergence 2020

    Development of Autoimmune Diseases and HLA Associations in Children with Neonatal Lupus and Their Unaffected Siblings

    Amit Saxena1, Aaron Garza Romero2, Daniel Gratch3, Peter Izmirly4, Hannah Ainsworth5, Miranda Marion5, Carl Langefeld6, Robert Clancy7 and Jill Buyon8, 1NYU School of Medicine, New York, 2Gonzaba Medical Group, San Antonio, 3NYU Langone Health, New York, 4Department of Medicine, New York University School of Medicine, New York, NY, 5Wake Forest School of Medicine, Winston-Salem, 6Wake Forest School of Medicine, Winston Salem, NC, 7New York University School of Medicine, New York, NY, 8Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Neonatal Lupus (NL) is a model of passively acquired autoimmunity conferred by exposure to maternal anti-Ro antibodies with major manifestations being congenital heart block…
  • Abstract Number: 1687 • ACR Convergence 2020

    Kawasaki Disease Shock Syndrome in the Intensive Care Unit: A Single Center Cohort

    Monica Bray1, Jennifer Rammel2, Andrea Ramirez1, Kristen Sexson1, Fong Lam1, Eyal Muscal3 and Marietta DeGuzman3, 1Baylor College of Medicine, Houston, TX, 2University of Florida Health Jacksonville, Jacksonville, FL, 3Baylor College of Medicine, Houston

    Background/Purpose: Kawasaki disease (KD), a well described vasculitis of childhood, is the leading cause of acquired heart disease in developed countries. Kawasaki disease shock syndrome…
  • Abstract Number: 0433 • ACR Convergence 2020

    Racial Disparities and New SLE-Specific Predictors of Stroke and Ischemic Heart Disease in Patients with Lupus

    Shivani Garg1, Christie Bartels2, Gaobin Bao3, Cristina Drenkard4 and S. Sam Lim3, 1UW Madison, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, 3Emory University, Atlanta, GA, 4Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA

    Background/Purpose: In the US, cardiovascular disease (CVD) is the leading cause of disparities in life expectancy between black and white populations. We recently reported a…
  • Abstract Number: 0562 • ACR Convergence 2020

    The Relationship Between Heart Disease Risk Profile and Osteoarthritis, Overall and by Multi-/Single-Joint Involvement

    Anthony Perruccio1, Shatabdy Zahid2, Calvin Yip3, J Denise Power2, Mayilee Canizares2, George Heckman4 and Elizabeth Badley1, 1Krembil Research Institute, UHN; University of Toronto, Toronto, ON, Canada, 2Krembil Research Institute, University Health Network, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4University of Waterloo, Waterloo, ON, Canada

    Background/Purpose: Osteoarthritis (OA) and heart disease (HD) are among the most common chronic conditions. Several studies have shown that OA increases the risk of HD…
  • Abstract Number: 0657 • ACR Convergence 2020

    Gout and Heart Failure in the US

    Gurkipal Singh1, Maanek Sehgal2 and Alka Mithal3, 1Stanford University, Stanford, CA, 2UCLA, Los Angeles, CA, 3ICORE, Woodside, CA

    Background/Purpose: Heart failure (HF) is the eighth leading cause of death in the US, with a 38% increase in the number of deaths due to…
  • Abstract Number: 0664 • ACR Convergence 2020

    Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction

    Ana B. Arevalo1, Alba Munoz2, Faris Haddadin2, Karan Sud2, Gustavo Contreras2, Shane Murray2, Yousaf Ali2 and Edgar Argulian2, 1Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York, NY, 2Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York

    Background/Purpose: Hyperuricemia (HUC) has been shown to have an impact in the left atrium and left ventricle remodeling leading to the development of heart failure…
  • Abstract Number: 1183 • ACR Convergence 2020

    Factors Associated with Incident Heart Failure Subtypes in Patients with Rheumatoid Arthritis Using Electronic Health Record Data

    Sicong Huang1, Tianrun Cai1, Brittany Weber1, Zeling He1, Kumar Dahal1, Chuan Hong2, Andrew Cagan3, Jacob Joseph4, Seoyoung Kim1, Daniel H Solomon1, Tianxi Cai2 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Harvard Medical School; Harvard T.H. Chan School of Public Health, Boston, MA, 3Partners Healthcare, Somerville, MA, 4Brigham and Women's Hospital; Veterans Affairs Boston Healthcare System, Boston, MA

    Background/Purpose: Heart failure (HF) is a major cause of mortality in rheumatoid arthritis (RA) and is broadly categorized into two subtypes, each with distinct pathophysiology:…
  • Abstract Number: 1184 • ACR Convergence 2020

    In a Prospective RA Cohort, Higher Baseline Disease Activity Is an Independent Predictor of Decline in Left Ventricular Diastolic Function

    Elizabeth Park1, Kazato Ito2, Christopher Depender1, Jon Giles1 and Joan Bathon1, 1Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 2Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY

    Background/Purpose: Rheumatoid Arthritis (RA) patients are at nearly 50% increased risk of heart failure (HF) compared to non-RA patients, despite adjusting for the presence of…
  • Abstract Number: 1187 • ACR Convergence 2020

    Red Cell Distribution Width Is Associated with ASCVD Risk Score and CVD in RA After Initiation of Methotrexate

    Ibtissam Gad1, Sofi Damjanovska2, Lenche Kostadinova3, Alyssa Lange4, Christopher Burant4, Brigid Wilson5, Taissa Bej5, Nora Singer6, Maya Mattar7, David Zidar8 and Donald Anthony9, 1Case Western Reserve/ Cleveland VA Medical Center, Cleveland Heights, OH, 2Case Western Reserve University/Cleveland VA Medical Center, Cleveland Heights, OH, 3(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Highland Heights, OH, 4Case Western Reserve University, Cleveland, 5Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, 6The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, 7Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, 8Case Western Reserve University/Cleveland VA Medical Center, Cleveland, 9Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH

    Background/Purpose: Rheumatoid arthritis (RA) has been shown to be associated with increased risk of cardiovascular disease (CVD)  and mortality. Red cell distribution width (RDW) represents…
  • Abstract Number: 377 • 2019 ACR/ARP Annual Meeting

    Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition

    Matthew Baker1, Khushboo Sheth 1, Julia Simard 2, Stanford Shoor 1 and Mark Genovese 3, 1Stanford University, Palo Alto, CA, 2Stanford University School of Medicine, Palo Alto, CA, 3Stanford University, Stanford, CA

    Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by the presence of noncaseating granulomas.  When it affects the myocardium, it can result in electrical conduction…
  • Abstract Number: 587 • 2019 ACR/ARP Annual Meeting

    Increased Prevalence of Cardiac Disorders in Dutch Ankylosing Spondylitis Patients: The CARDAS Study

    Milad Baniaamam1, Sjoerd Heslinga 2, Thelma Konings 3, Otto Kamp 3, Vokko van Halm 3, Irene van der Horst-Bruinsma 2 and Mike Nurmohamed 4, 1Amsterdam Rheumatology and immunology Center, Rheumatology, Reade, Amsterdam|Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, 3Amsterdam University Medical Center, location VUmc, Department of Cardiology, Amsterdam, Amsterdam, Netherlands, 4Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands

    Background/Purpose: The overall mortality rate in ankylosing spondylitis (AS) patients is increased by 60–90% compared with the general population. This higher mortality rate is predominately…
  • Abstract Number: 1564 • 2019 ACR/ARP Annual Meeting

    Renal Arteriosclerosis Predicts Cardiovascular Disease in Lupus Nephritis

    Shivani Garg1, Sarah Panzer 2, Karen Hansen 3, Callie Plafkin 4, Maureen Smith 2 and Christie Bartels 1, 1University of Wisconsin School of Medicine and Public Health, Madison, WI, 2UW-Madison, Madison, 3UW Madison, Madison, 4UW Health, Madison

    Background/Purpose: Patients with lupus nephritis (LN) have a 9-fold higher risk of cardiovascular disease (CVD), highlighting the urgent need to target CVD prevention. Studies in…
  • Abstract Number: 2330 • 2019 ACR/ARP Annual Meeting

    Factors Associated with Differing Types of Heart Failure in Patients with Rheumatoid Arthritis

    Sicong Huang1, Tianrun Cai 2, Daniel Solomon 3, Zeling He 1, Kumar Dahal 2, Chuan Hong 4, Andrew Cagan 5, Seoyoung C. Kim 6, Jacob Joseph 7, Tianxi Cai 8 and Katherine Liao 2, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, 3Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 4Harvard Medical School, Boston, MA, 5Research Information Science and Computing, Partners Healthcare, Boston, 6Brigham and Women’s Hospital and Harvard Medical School, Boston, 7Veterans Affairs Boston Healthcare System and Brigham and Women’s Hospital, Boston, MA, 8Harvard T.H. Chan School of Public Health, Boston

    Background/Purpose: For patients with rheumatoid arthritis (RA), heart failure (HF) is a significant cause of morbidity and mortality.  HF is further classified into 2 subtypes…
  • Abstract Number: 1527 • 2018 ACR/ARHP Annual Meeting

    Tofacitinib Improves Left Ventricular Mass and Cardiac Output in Rheumatoid Arthritis Patients with Chronic Heart Failure

    Kensuke Kume1, Kanzo Amano2, Susumu Yamada3, Toshikatsu Kanazawa3 and Kazuhiko Hatta4, 1Rheumatology, Hiroshima Clinic, Hiroshima, Japan, 2rheumatology., hiroshima clinic, Hiroshima, Japan, 3rheumatology, hiroshima clinic, hiroshima, Japan, 4Rheumatology, Hatta Clinic, Kure, Japan

    Background/Purpose: Rheumatologists need to develop primary and secondary prevention strategies for cardiovascular disease (CVD) in rheumatoid arthritis (RA) patients. We reported tofacitinib (Tofa) (with or…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology